



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Oxaliplatin (Standard)

Cat. No.:	HY-17371R
CAS No.:	61825-94-3
Molecular Formula:	C ₈ H ₁₄ N ₂ O ₄ Pt
Molecular Weight:	397.29
Target:	Apoptosis; DNA/RNA Synthesis
Pathway:	Apoptosis; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Oxaliplatin (Standard) is the analytical standard of Oxaliplatin. This product is intended for research and analytical applications. Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research ^{[1][2][3]} .
IC₅₀ & Target	IC50: DNA synthesis ^[1]

REFERENCES

- [1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. *Ann Oncol.* 1998 Oct;9(10):1053-71.
- [2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. *Anticancer Drugs.* 2000 Nov;11(10):859-63.
- [3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. *Cancer Res.* 1993 Dec 15;53(24):5970-6.
- [4]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. *Expert Opin Investig Drugs.* 2009 Nov;18(11):1595-604
- [5]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. *Biomed Pharmacother.* 1989;43(4):237-50.
- [6]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. *PLoS One.* 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.
- [7]. Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. *Proc Natl Acad Sci U S A.* 2012 Jul 24;109(30):11987-92.
- [8]. Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. *Biochim Biophys Acta.* 2009 Oct;1794(10):1433-40.
- [9]. Garrett MJ, et al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. *Hosp Pharm.* 2017 May;52(5):341-347.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA